Novo Nordisk Foundation / Novo Nordisk Fonden Revenue and Competitors

Claim your profile

Hellerup, Denmark



Total Funding



Estimated Revenue & Valuation

  • Novo Nordisk Foundation / Novo Nordisk Fonden's estimated annual revenue is currently $35M per year.(i)
  • Novo Nordisk Foundation / Novo Nordisk Fonden's estimated revenue per employee is $165,877

Employee Data

  • Novo Nordisk Foundation / Novo Nordisk Fonden has 211 Employees.(i)
  • Novo Nordisk Foundation / Novo Nordisk Fonden grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

The Novo Nordisk Foundation is a Danish foundation with corporate interests. The Foundation has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group(*); and 2) to support scientific, humanitarian and social purposes. The Foundation has a 90-year history and the vision is to contribute significantly to research and development that improves the health and welfare of people. Since 2010, the Foundation has donated more than EUR 2.1 billion (DKK 16 billion) for research, innovation, treatment, education and humanitarian and social purposes. Through its holding company Novo Holdings A/S the Foundation is a major shareholder in Novo Nordisk A/S and Novozymes A/S as well as more than 75 other companies. The Foundation awards grants for research, primarily at public universities and hospitals. While the main focus lies within biomedicine and biotechnology research, the Foundation also awards grants for research in general practice and family medicine, nursing and art history. All researchers have full publishing freedom and can decide their own research priorities. No Novo Group(*) company has preferential access to research results funded by grants from the Foundation. In recent years, the Foundation has increased its focus on innovation, diabetes treatment and grants for humanitarian and social purposes. In 2016 the Foundation awarded EUR 400 million (DKK 2.945 billion) to the Capital Region of Denmark to establish Steno Diabetes Center Copenhagen, a diabetes treatment and research institution. The Foundation gets its income from dividends and returns on investments in life-science companies and financial investments made by Novo Holdings A/S, a private limited liability company wholly owned by the Foundation and the holding company in the Novo Group and responsible for managing the Foundation's assets. (*) The Novo Group Companies: Novo Nordisk A/S, Novozymes A/S and NNIT A/S.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Novo Nordisk Foundation / Novo Nordisk Fonden News

2022-04-19 - SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

SNIPR BIOME and Novo Nordisk recently entered into a research ... Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the UK...

2022-04-13 - 3.4m EURO donated to WHO to help meet Ukraine's health needs ...

The Novo Nordisk Foundation has donated 25 million DKK (~3.4 million EUR), to the emergency ... Read more at

2022-03-30 - Novo Holdings reports Total Income and Returns of DKK 37 billion ...

We are very pleased to be executing on our key objective of generating attractive returns for the Novo Nordisk Foundation,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding